Advertisement
News
Advertisement

Mersana moves anti-cancer drug target along in trials

Fri, 03/25/2011 - 11:34am
Mass High Tech: The Journal of New England Technology

Mersana Therapeutics Inc., a Cambridge cancer therapeutics developer, has begun a Phase 1b extension study of its treatment for second-line gastric cancer and second- and third-line non-small cell lung cancer.

The anti-cancer treatment, XMT-1001, is a DNA topoisomerase I inhibitor that uses Mersana’s Fleximer polymer conjugate platform.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading